Management of chronic hepatitis B

Gastroenterology Clinics of North America

Volumn 33, Issue 3, 2004, Pages 563-579

  Ghany, Marc G ^a   Doo, Edward C ^b  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; CLEVUDINE; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; LOBUCAVIR; PYRIMIDINE DERIVATIVE; TENOFOVIR;

CHRONIC HEPATITIS; FEASIBILITY STUDY; GENOTYPE; HEPATITIS A VIRUS; HEPATITIS B; HISTORY OF MEDICINE; HUMAN; LIVER BIOPSY; MEDICAL ASSESSMENT; MOLECULAR RECOGNITION; PATIENT MONITORING; REVIEW; SEROCONVERSION;

ALGORITHMS; ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; GENOTYPE; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MASS SCREENING; PATIENT SELECTION;

EID: 8444251725     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gtc.2004.04.007     Document Type: Review

References (59)

1. World Health Organization Fact Sheet/204. Hepatitis B. 2000;World Health Organization, Geneva
2. Lee W.M. Hepatitis B virus infection. N Engl J Med. 337:(24):1997;1733- 1745
3. Lok A.S., Lai C.L. A longitudinal follow-up of asymptomatic hepatitis B surface antigen-positive Chinese children. Hepatology. 8:(5):1988;1130-1133
4. Guidotti L.G., Rochford R., Chung J., Shapiro M., Purcell R., Chisari F.V. Viral clearance without destruction of infected cells during acute HBV infection. Science. 284:(5415):1999;825-829
5. Hoofnagle J.H., Dusheiko G.M., Seeff L.B., Jones E.A., Waggoner J.G., Bales Z.B. Seroconversion from hepatitis B e antigen to antibody in chronic type B hepatitis. Ann Intern Med. 94:(6):1981;744-748
6. Di Bisceglie A.M., Waggoner J.G., Hoofnagle J.H. Hepatitis B virus deoxyribonucleic acid in liver of chronic carriers. Correlation with serum markers and changes associated with loss of hepatitis B e antigen after antiviral therapy. Gastroenterology. 93:(6):1987;1236-1241
7. Realdi G., Alberti A., Rugge M., et al. Seroconversion from hepatitis B e antigen to anti-HBe in chronic hepatitis B virus infection. Gastroenterology. 79:(2):1980;195-199
8. de Franchis R., Meucci G., Vecchi M., Tatarella M., Colombo M., Del Ninno E., et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med. 118:(3):1993;191-194
9. de Jongh F.E., Janssen H.L., de Man R.A., Hop W.C., Schalm S.W., van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology. 103:(5):1992;1630- 1635
10. Hoofnagle J.H., Shafritz D.A., Popper H. Chronic type B hepatitis and the healthy HBsAg carrier state. Hepatology. 7:(4):1987;758-763
11. Hadziyannis S.J., Vassilopoulos D. Hepatitis B e antigen-negative chronic hepatitis B. Hepatology. 34:2001;617-624
12. Carman W.F., Jacyna M.R., Hadziyannis S., Karayiannis P., McGarvey M.J., Makris A., et al. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 2:(8663):1989;588-591
13. Brunetto M.R., Stemler M., Bonino F., Schodel F., Oliveri F., Rizzetto M., et al. A new hepatitis B virus strain in patients with severe anti-HBe-positive chronic hepatitis B. J Hepatol. 10:(2):1990;258-261
14. Hadziyannis S. Hepatitis B e antigen-negative chronic hepatitis B: from clinical recognition to pathogenesis and treatment. Viral Hepatitis Review. 1:1995;7-36
15. Hsu Y.S., Chien R.N., Yeh C.T., Sheen I.S., Chiou H.Y., Chu C.M., et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 35:(6):2002;1522-1527
16. Lok A.S., Heathcote E.J., Hoofnagle J.H. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology. 120:(7):2001;1828-1853
17. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement. (short version) J Hepatol. 38:(4):2003;533-540
18. Okamoto H., Tsuda F., Sakugawa H., Sastrosoenignjo R.I., Imai M., Miyakana Y., et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol. 69:1988;2575-2583
19. Norder H., Courouce A.M., Magnius L.O. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology. 198:(2):1994;489-503
20. Stuyver L., De Gendt S., Van Geyt C., Zoulim F., Fried M., Schinazi R.F., et al. A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol. 81:(Pt 1):2000;67-74
21. Chu C.J., Keeffe E.B., Han S.H., Perello R.P., Min A.D., Soldevila-Pico C., et al. Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology. 125:(2):2003;444-451
22. Lindh M., Hannoun C., Dhillon A.P., Norkrans G., Horal P. Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis. 179:(4):1999;775-782
23. Chu C.J., Hussain M., Lok A.S. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology. 122:(7):2002;1756-1762
24. Orito E., Mizokami M., Sakugawa H., Michitaka K., Ishikana K., Iehida T., et al. A case-control study for clinical and molecular biological differences between hepatitis B viruses of genotypes B and C. Japan HBV Genotype Research Group. Hepatology. 33:(1):2001;218-223
25. Kao J.H., Chen P.J., Lai M.Y., Chen D.S. Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology. 118:(3):2000;554-559
26. Thakur V., Guptan R.C., Kazim S.N., Malhotra V., Sarin S.K. Profile, spectrum and significance of HBV genotypes in chronic liver disease patients in the Indian subcontinent. J Gastroenterol Hepatol. 17:(2):2002;165-170
27. Rodriguez-Frias F., Buti M., Jardi R., Cotrina M., Viladomina L., Esteban R., et al. Hepatitis B virus infection: precore mutants and its relation to viral genotypes and core mutations. Hepatology. 22:(6):1995;1641-1647
28. Kao J.H., Wu N.H., Chen P.J., Lai M.Y., Chen D.S. Hepatitis B genotypes and the response to interferon therapy. J Hepatol. 33:(6):2000;998-1002
29. Zollner B., Petersen J., Schroter M., Laufs R., Schoder V., Feucht H.H. 20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw. Lancet. 357:(9260):2001;934-935
30. Chien R.N., Yeh C.T., Tsai S.L., Chu C.M., Liaw Y.F. Determinants for sustained HBeAg response to lamivudine therapy. Hepatology. 38:(5):2003;1267- 1273
31. Westland C., Delaney W.T., Yang H., Chen S.S., Marcellin P., Hadziyannis S., et al. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology. 125:(1):2003;107-116
32. Mazzaferro V., Regalia E., Doci R., Andreola S., Palvirenti A., Bozzetti F., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 334:(11):1996;693-699
33. McMahon B.J., Bulkow L., Harpster A., Snowball M., Lanier A., Sacco F., et al. Screening for hepatocellular carcinoma in Alaska natives infected with chronic hepatitis B: a 16-year population-based study. Hepatology. 32:2000;842-846
34. McMahon B.J., London T. Workshop on screening for hepatocellular carcinoma. J Natl Cancer Inst. 83:(13):1991;916-919
35. van Nunen A.B., Hansen B.E., Suh D.J., Lohr H.F., Chemello L., Fontaine H., et al. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut. 52:(3):2003;420-424
36. Song B.C., Suh D.J., Lee H.C., Chung Y.H., Lee Y.S. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology. 32:2000;803-806
37. Dienstag J.L., Cianciara J., Karayalcin S., Kowdley K.V., Willems B., Plisek S., et al. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology. 37:(4):2003;748-755
38. de Man R.A., Wolters L.M., Nevens F., Chua D., Sherman M., Lou C.L., et al. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection. Hepatology. 34:(3):2001;578-582
39. Lai C.L., Rosmawati M., Lao J., Van Vlierberghe H., Anderson F.H., Thomas N., et al. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology. 123:(6):2002;1831-1838
40. Levine S., Hernandez D., Yamanaka G., Zhang S., Rose R., Weinheimer S., et al. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrob Agents Chemother. 46:(8):2002;2525-2532
41. Ying C., De Clercq E., Neyts J. Lamivudine, adefovir and tenofovir exhibit long-lasting anti-hepatitis B virus activity in cell culture. J Viral Hepat. 7:(1):2000;79-83
42. Nelson M., Portsmouth S., Stebbing J., Atkins M., Burr A., Matthews G., et al. An open-label study of tenofovir in HIV-1 and Hepatitis B virus coinfected individuals. AIDS. 17:(1):2003;F7-F10
43. Ying C., De Clercq E., Nicholson W., Furman P., Neyts J. Inhibition of the replication of the DNA polymerase M550V mutation variant of human hepatitis B virus by adefovir, tenofovir, L-FMAU, DAPD, penciclovir and lobucavir. J Viral Hepat. 7:(2):2000;161-165
44. Benhamou Y., Tubiana R., Thibault V. Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus. N Engl J Med. 348:(2):2003;177-178
45. Bruno R., Sacchi P., Zocchetti C., Ciappina V., Puoti M., Filice G. Rapid hepatitis B virus-DNA decay in co-infected HIV-hepatitis B virus e-minus patients with YMDD mutations after 4 weeks of tenofovir therapy. AIDS. 17:(5):2003;783-784
46. Bloomer J., Chen R., Sherman M., Ingraham P., De Hertogh D. A preliminary study of lobucavir for chronic hepatitis B. Hepatology. 26:1997;A1199
47. Doong S.L., Tsai C.H., Schinazi R.F., Liotta D.C., Cheng Y.C. Inhibition of the replication of hepatitis B virus in vitro by 2′,3′-dideoxy- 3′-thiacytidine and related analogues. Proc Natl Acad Sci U S A. 88:(19):1991;8495-8499
48. Korba B.E., Schinazi R.F., Cote P., Tennant B.C., Gerin J.L. Effect of oral administration of emtricitabine on woodchuck hepatitis virus replication in chronically infected woodchucks. Antimicrob Agents Chemother. 44:(6):2000;1757-1760
49. Gish R.G., Leung N.W., Wright T.L., Trinh H., Lang N., Kessler H.A., et al. Dose range study of pharmacokinetics, safety, and preliminary antiviral activity of emtricitabine in adults with hepatitis B virus infection. Antimicrob Agents Chemother. 46:(6):2002;1734-1740
50. Das K., Xiong X., Yang H., Westland C.E., Gibbs C.S., Saratianos S.G., et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol. 75:(10):2001;4771-4779
51. Chu C.K., Boudinot F.D., Peek S.F., Hong J.H., Choi Y., Korba B.E., et al. Preclinical investigation of L-FMAU as an antihepatitis B virus agent. Antivir Ther. 3:(Suppl 3):1998;113-121
52. Zhu Y., Yamamoto T., Cullen J., Saputelli J., Aldrich C.E., Miller D.S., et al. Kinetics of hepadnavirus loss from the liver during inhibition of viral DNA synthesis. J Virol. 75:(1):2001;311-322
53. Mewshaw J.P., Myrick F.T., Wakefield D.A., Hooper B.J., Harris J.L., McCrudy B., et al. Dioxolane guanosine, the active form of the prodrug diaminopurine dioxolane, is a potent inhibitor of drug-resistant HIV-1 isolates from patients for whom standard nucleoside therapy fails. J Acquir Immune Defic Syndr. 29:(1):2002;11-20
54. Seigneres B., Pichoud C., Martin P., Furman P., Trepo C., Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudine-resistant mutants of hepadnaviruses. Hepatology. 36:(3):2002;710-722
55. Standring D.N., Bridges E.G., Placidi L., Faraj A., Loi A.G., Pierra C., et al. Antiviral beta-L-nucleosides specific for hepatitis B virus infection. Antivir Chem Chemother. 12:(Suppl 1):2001;119-129
56. Doo E., Liang T.J. Molecular anatomy and pathophysiologic implications of drug resistance in hepatitis B virus infection. Gastroenterology. 120:(4):2001;1000-1008
57. Deres K., Schroder C.H., Paessens A., Goldman S., Hacker H.J., Weber O., et al. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science. 299:(5608):2003;893-896
58. Michel M.L., Pol S., Brechot C., Tiollais P. Immunotherapy of chronic hepatitis B by anti-HBV vaccine: from present to future. Vaccine. 19:2001;2395-2399
59. Shlomai A., Shaul Y. Inhibition of hepatitis B virus expression and replication by RNA interference. Hepatology. 37:(4):2003;764-770